Inthera Bioscience Overview
- Founded
- 2013
- Status
- Private
- Latest Deal Type
- Series A
- Latest Deal Amount
- $11.2M
- Investors
- 4
Inthera Bioscience General Information
Description
Developer of first-in-class targeted small molecule therapies designed to provide treatment for solid tumors. The company's therapies are focused on the development of novel first-in-class oral agents blocking aberrant cell signaling in solid tumors and uses proprietary technology platform to rationally design protein-protein interaction inhibitors, enabling patient to begin treatment more quickly and result in a higher likelihood of a successful treatment.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Drug Discovery
Primary Office
- Einsiedlerstrasse 34
- 8820 Waedenswil
- Switzerland
Inthera Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A) | 26-Jun-2018 | $11.2M | 000.00 | 000.00 | Completed | Pre-Clinical Trials |
| 2. Seed Round | 14-Dec-2015 | 00.000 | 00.000 | Completed | Product Development | |
| 1. Seed Round | 30-Apr-2014 | $226K | $226K | 00.000 | Completed | Generating Revenue |
Inthera Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 000,000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | ||
| Seed | 00,000 | 000.00 | 000.00 | 00 | 000.00 | 0.000 | ||
| Seed | 277,776 | $7.98 | $7.98 | 1x | $7.98 | 20.84% | ||
| Ordinary | 25,000 | $9.34 | $9.34 | 1x | $9.34 | 1.88% |
Inthera Bioscience Executive Team (7)
Inthera Bioscience Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Anker Lundemose Ph.D | Self | Board Member | 000 0000 |
| Emmanuelle Coutanceau Ph.D | Novo Holdings | Board Member | 000 0000 |
| Jasper Bos Ph.D | M Ventures | Board Member | 000 0000 |
| Keno Gutierrez Ph.D | M Ventures | Board Member | 000 0000 |
| Klaus Schollmeier Ph.D | Self | Chairman | 000 0000 |
Inthera Bioscience Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Aglaia Management B.V. | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Eva Capital | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
| M Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Novo Holdings | Venture Capital | Minority | 000 0000 | 000000 0 |